Results 31 to 40 of about 3,235 (226)

Sequential Use of Tezepelumab and Bronchoscopic Lung Volume Reduction With Endobronchial Valves in a Patient With Severe Asthma‐COPD Overlap and Heterogeneous Emphysema: A Case Report

Respirology Case Reports
Asthma‐COPD overlap (ACO) carries greater symptom burden, frequent exacerbations and impaired quality of life compared with asthma or COPD alone. Evidence‐based advanced therapies are lacking, and management is typically extrapolated from existing ...
Jonas Herth, Daniel Franzen
doaj   +2 more sources

One size does not fit all: uncontrolled T2 inflammation on tezepelumab—a case series [PDF]

Allergy, Asthma & Clinical Immunology
Background Tezepelumab is the most recent human monoclonal antibody in the therapeutic arsenal of patients with severe uncontrolled asthma. It neutralizes thymic stromal lymphopoietin (TSLP).
Arianne Tardif, Marie-Eve Boulay, Andréanne Côté, Krystelle Godbout   +3 more
doaj   +2 more sources

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study [PDF]

Advances in Therapy
Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks compared with placebo in ...
T. Carr, Wendy C. Moore, Monica Kraft, G. Brusselle, M. Castro, G. Chupp, M. Wechsler, G. Hunter, Andrew W. Lindsley, J. Llanos, Luke Burke, S. Chandarana, C. S. Ambrose   +12 more
semanticscholar   +2 more sources

Tezepelumab in severe asthma: chest computed tomography assessment of airway remodeling and clinical remission [PDF]

Frontiers in Pharmacology
IntroductionSevere asthma is characterized by persistent uncontrolled symptoms despite optimal standard therapy and/or by the need for high-intensity treatment to maintain control.
Chiara Lupia, Caterina Battaglia, Daniela Pastore, Youngjin Lee, Giovanna Lucia Piazzetta, Emanuela Chiarella, Nadia Lobello, Giovanni Sireno, Alessandro Pullano, Claudia Crimi, Alessandro Vatrella, Francesco Manti, Pier Paolo Arcuri, Domenico Laganà, Girolamo Pelaia, Corrado Pelaia   +15 more
doaj   +2 more sources

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy

Frontiers in Allergy
Even in eosinophilic granulomatosis with polyangiitis (EGPA), not all manifestations of eosinophilic inflammation respond equally to anti–interleukin-5 (IL-5) therapy.
Osamu Matsuno, Masahiro Kawamoto, Tansri Wibowo, Yutaka Ishida, Atsuhsi Ogata   +4 more
doaj   +2 more sources

The emerging role of anti-thymic stromal lymphopoietin monoclonal antibody (Tezepelumab) in comorbid and non-comorbid CRSwNP patients: a scoping review [PDF]

Brazilian Journal of Otorhinolaryngology
Objective: This systematic review aims to evaluate the effectiveness of Tezepelumab, a monoclonal antibody targeting the thymic stromal lymphopoietin, in patients affected by chronic rhinosinusitis with nasal polyposis, both with and without comorbid ...
Antonio Moffa, Eugenio de Corso, Domiziana Nardelli, Antonella Loperfido, Jacopo Galli, Peter Baptista, Manuele Casale   +6 more
doaj   +2 more sources

Reply to: Malik MMUD on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT). [PDF]

Int Forum Allergy Rhinol
International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 1060-1061, September 2026.
Mullol J, Han JK, Laidlaw TM, Hopkins C, Peters AT, Pfaar O, Desrosiers M, Lee SE, Lane AP, Chen C, Chon Y, Ponnarambil SS, Foster A, Lindsley AW, Ambrose CS.   +14 more
europepmc   +2 more sources

Navigating the small airways with tezepelumab. [PDF]

ERJ Open Res
Lim JV, Kuo CR, Chan R.
europepmc   +2 more sources

Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis

Cells, 2022
The anti-thymic stromal lymphopoietin antibody (tezepelumab) has therapeutical potential for inadequately controlled asthma. However, evidence comparing tezepelumab with other biologics is scarce.
Koichi Ando, Yosuke Fukuda, Akihiko Tanaka, Hironori Sagara   +3 more
doaj   +1 more source

Basophils and tezepelumab

Statistical model results for clinical, functional, and treatment outcomes after 12 months of tezepelumab ...
diana betancor
core   +6 more sources